Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Profit After Tax (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Profit After Tax for 16 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax fell 236.78% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$53.8 million, a 530.46% decrease, with the full-year FY2024 number at -$12.4 million, down 263.25% from a year prior.
  • Profit After Tax was -$1.2 million for Q3 2025 at Harvard Bioscience, up from -$2.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $2.4 million in Q2 2022 to a low of -$50.3 million in Q1 2025.
  • A 5-year average of -$3.9 million and a median of -$1.2 million in 2025 define the central range for Profit After Tax.
  • Biggest YoY gain for Profit After Tax was 693.9% in 2022; the steepest drop was 1902.94% in 2022.
  • Harvard Bioscience's Profit After Tax stood at $590000.0 in 2021, then plummeted by 382.37% to -$1.7 million in 2022, then fell by 9.12% to -$1.8 million in 2023, then skyrocketed by 100.99% to $18000.0 in 2024, then crashed by 6938.89% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Profit After Tax are -$1.2 million (Q3 2025), -$2.3 million (Q2 2025), and -$50.3 million (Q1 2025).